Figure 1

ARS Pharmaceuticals, Inc.

Treatment success rate with a single dose of neffy administered by a healthcare provider during oral food challenge and allergen immunotherapy during the neffy experience program (n = 545 patients) compared to historic control treatment success rate with a single dose of epinephrine injection administered by a healthcare provider during food-induced anaphylaxis as reported by Patel et. al. JACI, 2021 (n = 12,615 patients).

Format

PNG

Source

ARS Pharmaceuticals, Inc.

Downloads